NomosLogic Introduces Molecular Medicine Infrastructure for Consumer Genomics, Multi-Omic Fusion, and Deterministic Disease Modeling

SALT LAKE CITY--(BUSINESS WIRE)--NomosLogic, Inc. today introduced its molecular medicine infrastructure platform, designed to transform raw genomic files into clinically actionable intelligence across pharmacogenomics, disease susceptibility, and systems-level health modeling.

NomosLogic operates as an infrastructure layer for molecular medicine rather than a point product. Its integrated stack includes:

• TRINITY, a deterministic multi-omic fusion engine for pharmacogenomic interpretation and clinical decision support
• Hardy Bridge, a proprietary variant-phenotype mapping system translating raw variant data into clinically annotated context
• PROTEUS, a deterministic evolutionary simulation engine for modeling multi-variant disease architectures and distributed system behavior, k-anonymity enforcement.
• Chiron, a patient-facing interpretation layer that converts complex findings into consumer-ready health insights
• COVENANT, Resolves complete human genomes in 28 seconds. Classifies 38,324 variants into three deterministic states: Positive, Ruled Out, and Uncertain. 100% ACMG SF v3.2 secondary findings coverage with quality thresholds of GQ≥30 and DP≥20.
• The Sovereign Hash, Proprietary HMAC-SHA256 protocol that indexes biological data without exposing personally identifiable information. Double-blind architecture maintains physical separation between PII and multi-omic results.

Consumer genomics platforms, health systems, health plans, and biopharma organizations already sit on enormous genomic and clinical data assets. What is missing is the infrastructure layer that makes those assets clinically usable.

"Genomics has never really had an interpretation problem at the level of data availability. It has had an infrastructure problem. The data already exists. What has been missing is the molecular medicine layer that can deterministically turn that data into medication guidance, disease architecture, and health intelligence that people can actually use."

Matt Hardy, Founder & CEO, NomosLogic

NomosLogic's platform is designed to operate on existing raw DNA file formats, VCFs, and broader clinical data inputs, enabling partners to unlock value from data they already possess rather than rebuilding their genomic stack from scratch. The company's infrastructure supports consumer genomics interpretation, clinical genomics workflows, health-plan scale deployment, and research use cases in evolutionary pharmaceutical discovery.

The platform is protected by a broad patent portfolio spanning nomenclature resolution, deterministic clinical logic architecture, multi-omic fusion, evolutionary simulation, and state-faithful systems visualization. NomosLogic is currently in active clinical validation and partnership discussions across consumer genomics, payer, and pharmaceutical markets.

About NomosLogic

NomosLogic is building infrastructure for molecular medicine. The company's platform integrates deterministic genomic interpretation, multi-omic fusion, distributed disease modeling, patient-facing insight generation, and governance-grade auditability into a unified infrastructure layer for health systems, consumer genomics platforms, payers, and biopharma.